Publications

  1. Sakata KK, Midthun DE, Mullon JJ, Kern RM, Nelson DR, Edell ES, Schiavo DN, Jett JR, Aubry MC. Comparison of Programmed Death Ligand-1 Immunohistochemical Staining Between Endobronchial Ultrasound Transbronchial Needle Aspiration and Resected Lung Cancer Specimens. Chest. 2018 Oct; 154 (4):827-837 Epub 2018 July 27
    View PubMed
  2. Niska JR, Schild SE, Rule WG, Daniels TB, Jett JR. Fatal Radiation Pneumonitis in Patients With Subclinical Interstitial Lung Disease. Clin Lung Cancer. 2018 Jul; 19 (4):e417-e420 Epub 2018 Feb 17
    View PubMed
  3. Schild SE, Hillman SL, Tan AD, Ross HJ, McGinnis WL, Garces YA, Graham DL, Adjei AA, Jett JR, Mayo Clinic, North Central Cancer Treatment Group. Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol. 2017 Apr; 12 (4):697-703 Epub 2017 Jan 12
    View PubMed
  4. Ak G, Tomaszek SC, Kosari F, Metintas M, Jett JR, Metintas S, Yildirim H, Dundar E, Dong J, Aubry MC, Wigle DA, Thomas CF Jr. MicroRNA and mRNA features of malignant pleural mesothelioma and benign asbestos-related pleural effusion. Biomed Res Int. 2015; 2015:635748 Epub 2015 Feb 01
    View PubMed
  5. Birse CE, Lagier RJ, FitzHugh W, Pass HI, Rom WN, Edell ES, Bungum AO, Maldonado F, Jett JR, Mesri M, Sult E, Joseloff E, Li A, Heidbrink J, Dhariwal G, Danis C, Tomic JL, Bruce RJ, Moore PA, He T, Lewis ME, Ruben SM. Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium. Clin Proteomics. 2015; 12 (1):18 Epub 2015 July 16
    View PubMed
  6. Kernstine KH, Moon J, Kraut MJ, Pisters KM, Sonett JR, Rusch VW, Thomas CR Jr, Waddell TK, Jett JR, Lyss AP, Keller SM, Gandara DR, American College of Surgeons Oncology Group//Cancer and Leukemia Group B//Eastern Cooperative Oncology Group//North Central Cancer Treatment Group//National Cancer Institute of Canada Clinical Trials Group//Southwest Oncology Group. Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg. 2014 Aug; 98 (2):402-10 Epub 2014 June 28
    View PubMed
  7. Maldonado F, Jett JR. Invasive and noninvasive advances in the staging of lung cancer. Semin Oncol. 2014 Feb; 41(1):17-27. Epub 2013 Dec 12
    View PubMed
  8. Voss JS, Iqbal S, Jenkins SM, Henry MR, Clayton AC, Jett JR, Kipp BR, Halling KC, Maldonado F. Development of a multivariate model to predict the likelihood of carcinoma in patients with indeterminate peripheral lung nodules after a nondiagnostic bronchoscopic evaluation. Hum Pathol. 2014 Jan; 45(1):41-7. Epub 2013 Oct 16
    View PubMed
  9. Midthun DE, Jett JR. Screening for lung cancer: the US studies. J Surg Oncol. 2013 Oct; 108(5):275-9. Epub 2013 Aug 05.
    View PubMed
  10. Kumar SK, Jett J, Marks R, Richardson R, Quevedo F, Moynihan T, Croghan G, Markovic SN, Bible KC, Qin R, Tan A, Molina J, Kaufmann SH, Erlichman C, Adjei AA. Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies. Invest New Drugs. 2013 Oct; 31 (5):1201-6 Epub 2013 July 26
    View PubMed
  11. Jett JR, Schild SE, Kesler KA, Kalemkerian GP. Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May; 143 (5 Suppl):e400S-e419S
    View PubMed
  12. Limburg PJ, Mandrekar SJ, Aubry MC, Ziegler KL, Zhang J, Yi JE, Henry M, Tazelaar HD, Lam S, McWilliams A, Midthun DE, Edell ES, Rickman OB, Mazzone P, Tockman M, Beamis JF, Lamb C, Simoff M, Loprinzi C, Szabo E, Jett J, Cancer Prevention Network. Randomized phase II trial of sulindac for lung cancer chemoprevention. Lung Cancer. 2013 Mar; 79 (3):254-61 Epub 2012 Dec 20
    View PubMed
  13. Pecot CV, Li M, Zhang XJ, Rajanbabu R, Calitri C, Bungum A, Jett JR, Putnam JB, Callaway-Lane C, Deppen S, Grogan EL, Carbone DP, Worrell JA, Moons KG, Shyr Y, Massion PP. Added value of a serum proteomic signature in the diagnostic evaluation of lung nodules. Cancer Epidemiol Biomarkers Prev. 2012 May; 21(5):786-92. Epub 2012 Feb 28.
    View PubMed
  14. Reungwetwattana T, Molina JR, Mandrekar SJ, Allen-Ziegler K, Rowland KM, Reuter NF, Luyun RF, Dy GK, Marks RS, Schild SE, Jett JR, Adjei AA. Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. J Thorac Oncol. 2012 May; 7 (5):919-22
    View PubMed
  15. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, Shepherd FA. Non-small-cell lung cancer. Lancet. 2011 Nov 12; 378(9804):1727-40. Epub 2011 May 10.
    View PubMed
  16. Jett JR, Midthun DE. Screening for lung cancer: for patients at increased risk for lung cancer, it works. Ann Intern Med. 2011 Oct 18; 155(8):540-2. Epub 2011 Sep 05.
    View PubMed
  17. Cuffe S, Moua T, Summerfield R, Roberts H, Jett J, Shepherd FA. Characteristics and outcomes of small cell lung cancer patients diagnosed during two lung cancer computed tomographic screening programs in heavy smokers. J Thorac Oncol. 2011 Apr; 6(4):818-22.
    View PubMed
  18. Foster NR, Qi Y, Shi Q, Krook JE, Kugler JW, Jett JR, Molina JR, Schild SE, Adjei AA, Mandrekar SJ. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Cancer. 2011 Mar 15; 117 (6):1262-71 Epub 2010 Oct 19
    View PubMed
  19. Maldonado F, Bartholmai BJ, Swensen SJ, Midthun DE, Decker PA, Jett JR. Are airflow obstruction and radiographic evidence of emphysema risk factors for lung cancer? A nested case-control study using quantitative emphysema analysis. Chest. 2010 Dec; 138(6):1295-302. Epub 2010 Mar 26.
    View PubMed
  20. Bryce AH, Mattar B, Hillman SL, Adjei AA, Kugler JW, Rowland K Jr, Wender DB, Soori G, Perez EA, Jett JR. Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study. Am J Clin Oncol. 2010 Aug; 33 (4):353-7
    View PubMed
  21. Maldonado F, Jett JR. Advances in the diagnosis of lung cancer: contribution of molecular biology to bronchoscopic diagnosis. Curr Opin Pulm Med. 2010 Jul; 16(4):315-20.
    View PubMed
  22. Chee CE, Jett JR, Bernath AM Jr, Foster NR, Nelson GD, Molina J, Nikcevich DA, Steen PD, Flynn PJ, Rowland KM Jr. Phase 2 trial of pemetrexed disodium and carboplatin in previously untreated extensive-stage small cell lung cancer, N0423. Cancer. 2010 May 15; 116 (10):2382-9
    View PubMed
  23. Voss JS, Kipp BR, Halling KC, Henry MR, Jett JR, Clayton AC, Rickman OB. Fluorescence in situ hybridization testing algorithm improves lung cancer detection in bronchial brushing specimens. Am J Respir Crit Care Med. 2010 Mar 1; 181(5):478-85. Epub 2009 Dec 10.
    View PubMed
  24. Lindell RM, Hartman TE, Swensen SJ, Jett JR, Midthun DE, Mandrekar JN. 5-year lung cancer screening experience: growth curves of 18 lung cancers compared to histologic type, CT attenuation, stage, survival, and size. Chest. 2009 Dec; 136 (6):1586-1595 Epub 2009 July 06
    View PubMed
  25. Heffner JE, Holgate ST, Chung KF, Niederman MS, Daley CL, Jett JR, Stradling JR, Wells AU, Light RW, Tapson VF, Hansell DM, Provonost PJ, Lee YC. Road ahead to respiratory health: experts chart future research directions. Respirology. 2009 Jul; 14(5):625-36. Epub 2009 Mar 11.
    View PubMed
  26. Wilcox BE, Subramaniam RM, Peller PJ, Aughenbaugh GL, Nichols Iii FC, Aubry MC, Jett JR. Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma. Clin Lung Cancer. 2009 Jul; 10: (4)244-8.
    View PubMed
  27. Foster NR, Mandrekar SJ, Schild SE, Nelson GD, Rowland KM Jr, Deming RL, Kozelsky TF, Marks RS, Jett JR, Adjei AA. Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials. Cancer. 2009 Jun 15; 115 (12):2721-31
    View PubMed
  28. Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009 May 20; 27(15):2530-5. Epub 2009 Apr 06.
    View PubMed
  29. Yang P, Mandrekar SJ, Hillman SH, Allen Ziegler KL, Sun Z, Wampfler JA, Cunningham JM, Sloan JA, Adjei AA, Perez E, Jett JR. Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: an NCCTG-97-24-51 based study. J Thorac Oncol. 2009 Apr; 4 (4):479-85
    View PubMed
  30. Subramaniam RM, Wilcox B, Aubry MC, Jett J, Peller PJ. 18F-fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma. J Med Imaging Radiat Oncol. 2009 Apr; 53: (2)160-9; quiz 170.
    View PubMed
  31. Travis WD, Giroux DJ, Chansky K, Crowley J, Asamura H, Brambilla E, Jett J, Kennedy C, Rami-Porta R, Rusch VW, Goldstraw P, International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2008 Nov; 3(11):1213-23.
    View PubMed
  32. Lim E, Goldstraw P, Nicholson AG, Travis WD, Jett JR, Ferolla P, Bomanji J, Rusch VW, Asamura H, Skogseid B, Baudin E, Caplin M, Kwekkeboom D, Brambilla E, Crowley J. Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007. J Thorac Oncol. 2008 Oct; 3(10):1194-201.
    View PubMed
  33. Patel RR, Subramaniam RM, Mandrekar JN, Hammack JE, Lowe VJ, Jett JR. Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis. Mayo Clin Proc. 2008 Aug; 83: (8)917-22.
    View PubMed
  34. Mateen FJ, Jatoi A, Lineberry TW, Aranguren D, Creagan ET, Croghan GA, Jett JR, Marks RS, Molina JR, Richardson RL. Do patients with schizophrenia receive state-of-the-art lung cancer therapy? A brief report. Psychooncology. 2008 Jul; 17 (7):721-5
    View PubMed
  35. Midthun DE, Jett JR. Update on screening for lung cancer. Semin Respir Crit Care Med. 2008 Jun; 29 (3):233-40
    View PubMed
  36. Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DH, Crowley JJ, Gandara DR. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008 May 20; 26(15):2450-6. Epub 2008 Mar 31.
    View PubMed
  37. Johnson EA, Marks RS, Mandrekar SJ, Hillman SL, Hauge MD, Bauman MD, Wos EJ, Moore DF, Kugler JW, Windschitl HE, Graham DL, Bernath AM Jr, Fitch TR, Soori GS, Jett JR, Adjei AA, Perez EA. Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). Lung Cancer. 2008 May; 60 (2):200-7 Epub 2007 Nov 28
    View PubMed
  38. Jett JR, Midthun DE. Commentary: CT screening for lung cancer--caveat emptor. Oncologist. 2008 Apr; 13: (4)439-44.
    View PubMed
  39. Brawner EJ, Nana-Sinkam SP, Jett JR. Lung cancer screening in 2008: A review and update. Respiratory Medicine CME. 2008; 1(1):2-9.
  40. Jett JR, Schild SE, Keith RL, Kesler KA, American College of Chest Physicians. Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 Sep; 132 (3 Suppl):266S-276S
    View PubMed
  41. Bach PB, Silvestri GA, Hanger M, Jett JR, American College of Chest Physicians. Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 Sep; 132(3 Suppl):69S-77S.
    View PubMed
  42. Schild SE, Mandrekar SJ, Jatoi A, McGinnis WL, Stella PJ, Deming RL, Jett JR, Garces YI, Allen KL, Adjei AA, North Central Cancer Treatment GroupThis study was conducted as a collaborative trial of the North Central Cancer Treatment Group and the Mayo Clinic. The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. Cancer. 2007 Jul 15; 110(2):363-8.
    View PubMed
  43. Rami-Porta R, Ball D, Crowley J, Giroux DJ, Jett J, Travis WD, Tsuboi M, Vallieres E, Goldstraw P, International Staging Committee, Cancer Research and Biostatistics, Observers to the Committee, Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2007 Jul; 2(7):593-602.
    View PubMed
  44. Aubry MC, Thomas CF Jr, Jett JR, Swensen SJ, Myers JL. Significance of multiple carcinoid tumors and tumorlets in surgical lung specimens: analysis of 28 patients. Chest. 2007 Jun; 131: (6)1635-43.
    View PubMed
  45. Adjei AA, Molina JR, Mandrekar SJ, Marks R, Reid JR, Croghan G, Hanson LJ, Jett JR, Xia C, Lathia C, Simantov R. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res. 2007 May 1; 13(9):2684-91.
    View PubMed
  46. Garces YI, Okuno SH, Schild SE, Mandrekar SJ, Bot BM, Martens JM, Wender DB, Soori GS, Moore DF Jr, Kozelsky TF, Jett JR. Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2007 Mar 15; 67 (4):995-1001
    View PubMed
  47. Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB. Computed tomography screening and lung cancer outcomes. JAMA. 2007 Mar 7; 297(9):953-61.
    View PubMed
  48. Huschka MM, Mandrekar SJ, Schaefer PL, Jett JR, Sloan JA. A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials. Cancer. 2007 Feb 15; 109 (4):787-95
    View PubMed
  49. Lindell RM, Hartman TE, Swensen SJ, Jett JR, Midthun DE, Tazelaar HD, Mandrekar JN. Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers. Radiology. 2007 Feb; 242 (2):555-62
    View PubMed
  50. Daniels CE, Lowe VJ, Aubry MC, Allen MS, Jett JR. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest. 2007 Jan; 131: (1)255-60.
    View PubMed
  51. Gandara DR, Aberle D, Lau D, Jett J, Akhurst T, Heelan R, Mulshine J, Berg C, Patz EF Jr. Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. J Thorac Oncol. 2006 Nov; 1(9 Suppl):S20-6.
    View PubMed
  52. Molina JR, Adjei AA, Jett JR. Advances in chemotherapy of non-small cell lung cancer. Chest. 2006 Oct; 130 (4):1211-9
    View PubMed
  53. Halling KC, Rickman OB, Kipp BR, Harwood AR, Doerr CH, Jett JR. A comparison of cytology and fluorescence in situ hybridization for the detection of lung cancer in bronchoscopic specimens. Chest. 2006 Sep; 130 (3):694-701
    View PubMed
  54. Mandrekar SJ, Schild SE, Hillman SL, Allen KL, Marks RS, Mailliard JA, Krook JE, Maksymiuk AW, Chansky K, Kelly K, Adjei AA, Jett JR. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer. 2006 Aug 15; 107(4):781-92.
    View PubMed
  55. Schild SE, McGinnis WL, Graham D, Hillman S, Fitch TR, Northfelt D, Garces YI, Shahidi H, Tschetter LK, Schaefer PL, Adjei A, Jett J. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):1106-11. Epub 2006 May 26.
    View PubMed
  56. Zhong L, Coe SP, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thor Oncol. 2006 Jul; 1(6):513-9.
  57. Mandrekar SJ, Northfelt DW, Schild SE, Foster NR, Bot B, Marks RS, Mailliard JA, Krook JE, Maksymiuk AW, Adjei AA, Jett JR. Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trials. J Thorac Oncol. 2006 Jul; 1(6):556-63.
    View PubMed
  58. Molina JR, Nikcevich D, Hillman S, Geyer S, Drevyanko T, Jett J, Verdirame J, Tazelaar H, Rowland K, Wos E, Kutteh L, Nair S, Fitch T, Flynn P, Stella P, Adjei AA. A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer. Cancer Invest. 2006 Jun-Jul; 24 (4):382-9
    View PubMed
  59. Molina JR, Jett JR, Foster N, Lair BS, Carroll TJ, Tazelaar HD, Hillman S, Mailliard JA, Bernath AM Jr, Nikcevich D. Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer. Am J Clin Oncol. 2006 Jun; 29(3):246-51.
    View PubMed
  60. Jett JR, Miller YE. Update in lung cancer 2005. Am J Respir Crit Care Med. 2006 Apr 1; 173(7):695-7.
    View PubMed
  61. Dy GK, Jett JR, Geoffroy FJ, Krewer KD, Tazelaar H, Maurer M, Rowland K, Mailliard J, Krook J, Dakhil S, Kutteh L, Kugler J, Wender D. Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial of the North Central Cancer Treatment Group. J Thorac Oncol. 2006 Mar; 1 (3):211-7
    View PubMed
  62. Thomas CF Jr, Jett JR. Bronchial Carcinoid Tumors. UpToDate. 2006.
  63. Jatoi A, Hillman S, Stella P, Green E, Adjei A, Nair S, Perez E, Amin B, Schild SE, Castillo R, Jett JR, North Central Cancer Treatment Group. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol. 2005 Dec 20; 23(36):9113-9.
    View PubMed
  64. Zhong L, Hidalgo GE, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Using protein microarray as a diagnostic assay for non-small cell lung cancer. Am J Respir Crit Care Med. 2005 Nov 15; 172(10):1308-14.
    View PubMed
  65. Dy GK, Miller AA, Mandrekar SJ, Aubry MC, Langdon RM Jr, Morton RF, Schild SE, Jett JR, Adjei AA. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol. 2005 Nov; 16 (11):1811-6 Epub 2005 Aug 08
    View PubMed
  66. Ma CX, Nair S, Thomas S, Mandrekar SJ, Nikcevich DA, Rowland KM, Fitch TR, Windschitl HE, Hillman SL, Schild SE, Jett JR, Obasaju C, Adjei AA, North Central Cancer Treatment Group//Mayo Clinic//Eli Lilly & Company. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol. 2005 Sep 1; 23 (25):5929-37
    View PubMed
  67. Daniels CE, Jett JR. Does interstitial lung disease predispose to lung cancer? Curr Opin Pulm Med. 2005 Sep; 11 (5):431-7
    View PubMed
  68. Giordano KF, Jatoi A, Adjei AA, Creagan ET, Croghan G, Frytak S, Jett JR, Marks R, Molina J, Okuno S, Richardson RL. Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institution. Lung Cancer. 2005 Aug; 49(2):209-15. Epub 2005 Apr 13.
    View PubMed
  69. Lindell RM, Hartman TE, Swensen SJ, Jett JR, Midthun DE, Nathan MA, Lowe VJ. Lung cancer screening experience: a retrospective review of PET in 22 non-small cell lung carcinomas detected on screening chest CT in a high-risk population. AJR Am J Roentgenol. 2005 Jul; 185 (1):126-31
    View PubMed
  70. Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, Thibodeau S, Adjei AA, Jett J, Deschamps C. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005 Jul; 128 (1):452-62
    View PubMed
  71. Jett JR. Limitations of screening for lung cancer with low-dose spiral computed tomography. Clin Cancer Res. 2005 Jul 01; 11: (13 Pt 2)4988s-4992s.
    View PubMed
  72. Ashton RW, Jett JR. Screening for non-small cell lung cancer. Semin Oncol. 2005 Jun; 32 (3):253-8
    View PubMed
  73. Schild SE, Stella PJ, Brooks BJ, Mandrekar S, Bonner JA, McGinnis WL, Mailliard JA, Krook JE, Deming RL, Adjei AA, Jatoi A, Jett JR. Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer. 2005 Jun 1; 103(11):2349-54.
    View PubMed
  74. Townsend CO, Clark MM, Jett JR, Patten CA, Schroeder DR, Nirelli LM, Swensen SJ, Hurt RD. Relation between smoking cessation and receiving results from three annual spiral chest computed tomography scans for lung carcinoma screening. Cancer. 2005 May 15; 103: (10)2154-62.
    View PubMed
  75. Swensen SJ, Jett JR, Hartman TE, Midthun DE, Mandrekar SJ, Hillman SL, Sykes AM, Aughenbaugh GL, Bungum AO, Allen KL. CT screening for lung cancer: five-year prospective experience. Radiology. 2005 Apr; 235 (1):259-65 Epub 2005 Feb 04
    View PubMed
  76. Strauss GM, Dominioni L, Jett JR, Freedman M, Grannis FW. Como international conference position statement - Lung cancer screening for early diagnosis 5 years after the 1998 Varese Conference. Chest. 2005 Apr; 127(4):1146-51.
    View PubMed
  77. Burke L, Flieder DB, Guinee DG, Brambilla E, Freedman AN, Bennett WP, Jones RT, Borkowski A, Caporaso NA, Fleming M, Trastek V, Pairolero P, Tazelaar H, Midthun D, Jett JR, Liotta LA, Travis WD, Harris CC. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. Clin Cancer Res. 2005 Jan 1; 11(1):232-41.
    View PubMed
  78. Amin B, Hillman S, Nikcevich D, Dakhil S, Mailliard J, Fitch T, Bernath, Jr. A, Jett J, Perez E. Randomized Phase II Study of Docetaxel and Gemcitabine for Stage IIIB/IV Non-Small Cell Lung Cancer: An NCCTG study Lung Cancer. 2005.
  79. Jatoi A, Jett JR, Sloan J, Novotny P, Ford J, Prabhakar U, Loprinzi CL. A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients. Support Care Cancer. 2004 Dec; 12 (12):859-63 Epub 2004 Sept 15
    View PubMed
  80. David O, Jett J, LeBeau H, Dy G, Hughes J, Friedman M, Brody AR. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res. 2004 Oct 15; 10(20):6865-71.
    View PubMed
  81. Svobodnik A, Yang P, Novotny PJ, Bass E, Garces YI, Jett JR, Bonner JA, Sloan JA. Quality of life in 650 lung cancer survivors 6 months to 4 years after diagnosis. Mayo Clin Proc. 2004 Aug; 79 (8):1024-30
    View PubMed
  82. Crestanello JA, Allen MS, Jett JR, Cassivi SD, Nichols FC 3rd, Swensen SJ, Deschamps C, Pairolero PC. Thoracic surgical operations in patients enrolled in a computed tomographic screening trial. J Thorac Cardiovasc Surg. 2004 Aug; 128 (2):254-9
    View PubMed
  83. Schild SE, Bonner JA, Shanahan TG, Brooks BJ, Marks RS, Geyer SM, Hillman SL, Farr GH Jr, Tazelaar HD, Krook JE, Geoffroy FJ, Salim M, Arusell RM, Mailliard JA, Schaefer PL, Jett JR. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004 Jul 15; 59 (4):943-51
    View PubMed
  84. Kraemer PS, Sanchez CA, Goodman GE, Jett J, Rabinovitch PS, Reid BJ. Flow cytometric enrichment for respiratory epithelial cells in sputum. Cytometry Part A. 2004 Jul; 60A(1):1-7.
  85. Visbal AL, Williams BA, Nichols FC 3rd, Marks RS, Jett JR, Aubry MC, Edell ES, Wampfler JA, Molina JR, Yang P. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg. 2004 Jul; 78 (1):209-15; discussion 215
    View PubMed
  86. Jett JR, Midthun DE. Screening for lung cancer: current status and future directions: Thomas A. Neff lecture. Chest 2004 May; 125 (5 Suppl):158S-62S
    View PubMed
  87. Clark MM, Cox LS, Jett JR, Patten CA, Schroeder DR, Nirelli LM, Vickers K, Hurt RD, Swensen SJ. Effectiveness of smoking cessation self-help materials in a lung cancer screening population. Lung Cancer. 2004 Apr; 44 (1):13-21
    View PubMed
  88. Nadrous HF, Allen MS, Bartholmai BJ, Aughenbaugh GL, Lewis JT, Jett JR. Glomus tumor of the trachea: value of multidetector computed tomographic virtual bronchoscopy. Mayo Clin Proc. 2004 Feb; 79(2):237-40.
    View PubMed
  89. Ramalingam S, Belani CP, Day R, Zamboni BA, Jacobs SA, Jett JR. Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer. Ann Oncol. 2004 Feb; 15(2):247-51.
    View PubMed
  90. Cox LS, Clark MM, Jett JR, Patten CA, Schroeder DR, Nirelli LM, Swensen SJ, Hurt RD. Change in smoking status after spiral chest computed tomography scan screening. Cancer. 2003 Dec 1; 98(11):2495-501.
    View PubMed
  91. Ma CX, Hobday TJ, Jett JR. Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin Proc. 2003 Dec; 78(12):1578-9.
    View PubMed
  92. Jett JR. Superior sulcus tumors and Pancoast's syndrome. Lung Cancer. 2003 Dec; 42 Suppl 2:S17-21
    View PubMed
  93. Jatoi A, Stella PJ, Hillman S, Mailliard JA, Vanone S, Perez EA, Cannon MW, Geyer S, Wiesenfeld M, Jett JR. Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (>or=65 years of age): a phase II North Central Cancer Treatment Group study. Am J Clin Oncol. 2003 Oct; 26(5):441-7.
    View PubMed
  94. Swensen SJ, Jett JR, Midthun DE, Hartman TE. Computed tomographic screening for lung cancer: home run or foul ball? Mayo Clin Proc. 2003 Sep; 78 (9):1187-8
    View PubMed
  95. Schild SE, Stella PJ, Geyer SM, Bonner JA, McGinnis WL, Mailliard JA, Brindle J, Jatoi A, Jett JR, North Central Cancer Treatment Group. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol. 2003 Sep 1; 21 (17):3201-6 Epub 2003 July 21
    View PubMed
  96. Jatoi A, Hillman S, Stella PJ, Mailliard JA, Sloan J, Vanone S, Cannon MW, Kutteh L, Kanard A, Jett JR. Daily activities: exploring their spectrum and prognostic impact in older, chemotherapy-treated lung cancer patients. Support Care Cancer. 2003 Jul; 11 (7):460-4 Epub 2003 Mar 12
    View PubMed
  97. Jett JR, Hatfield AK, Hillman S, Bauman MD, Mailliard JA, Kugler JW, Morton RF, Marks RS, Levitt R. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group. Cancer. 2003 May 15; 97(10):2498-503.
    View PubMed
  98. Swensen SJ, Jett JR, Hartman TE, Midthun DE, Sloan JA, Sykes AM, Aughenbaugh GL, Clemens MA. Lung cancer screening with CT: Mayo Clinic experience. Radiology. 2003 Mar; 226 (3):756-61 Epub 2003 Jan 24
    View PubMed
  99. Jett JR, Scott WJ, Rivera MP, Sause WT, American College of Chest Physicians. Guidelines on treatment of stage IIIB non-small cell lung cancer. Chest. 2003 Jan; 123 (1 Suppl):221S-225S
    View PubMed
  100. Jatoi A, Hillman S, Stella P, Mailliard J, Sloan J, Vanone S, Cannon M, Kutteh L, Kanard A, Jett J. Activities of Daily Living: Exploring their Spectrum and Prognostic Impact in Older, Chemotherapy-Treated Lung Cancer Patients Supportive Care in Cancer. 2003; 7:460-464.
  101. Jett J, Hatfield A, Hillman S, Bauman M, Mailliard J, Kugler J, Morton R, Marks R, Levitt R. Alternating Chemotherapy with Etoposide/Cisplatin and Topotecan/Paclitaxel in Patients with Untreated Extensive Stage Small Cell Lung Cancer: A Phase II Trial of the North Central Cancer Treatment Group Cancer. 2003:2498-2503.
  102. Colby TV, Tazelaar HD, Travis WD, Bergstralh EJ, Jett JR. Pathologic review of the Mayo Lung Project - Is there a case for misdiagnosis or overdiagnosis of lung carcinoma in the screened group? Cancer. 2002 Dec 1; 95(11):2361-5.
    View PubMed
  103. Schild SE, Stella PJ, Geyer SM, Bonner JA, Marks RS, McGinnis WL, Goetz SP, Kuross SA, Mailliard JA, Kugler JW, Schaefer PL, Jett JR. Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002 Oct 1; 54 (2):370-8
    View PubMed
  104. Jett JR. How to optimize staging in early non-small cell lung cancer. Lung Cancer. 2002 Oct; 38 (1):S13-6
    View PubMed
  105. Kishi K, Gurney JW, Schroeder DR, Scanlon PD, Swensen SJ, Jett JR. The correlation of emphysema or airway obstruction with the risk of lung cancer: a matched case-controlled study. Eur Respir J. 2002 Jun; 19(6):1093-8.
    View PubMed
  106. Taniguchi K, Yang P, Jett J, Bass E, Meyer R, Wang Y, Deschamps C, Liu W. Polymorphisms in the promoter region of the neutrophil elastase gene are associated with lung cancer development. Clin Cancer Res. 2002 Apr; 8(4):1115-20.
    View PubMed
  107. Yang P, Yokomizo A, Tazelaar HD, Marks RS, Lesnick TG, Miller DL, Sloan JA, Edell ES, Meyer RL, Jett J, Liu W. Genetic determinants of lung cancer short-term survival: the role of glutathione-related genes. Lung Cancer. 2002 Mar; 35 (3):221-9
    View PubMed
  108. Swensen SJ, Jett JR, Sloan JA, Midthun DE, Hartman TE, Sykes AM, Aughenbaugh GL, Zink FE, Hillman SL, Noetzel GR, Marks RS, Clayton AC, Pairolero PC. Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med. 2002 Feb 15; 165 (4):508-13
    View PubMed
  109. Sloan JA, Bonner JA, Hillman SL, Allmer C, Shanahan TG, Brooks BJ, Marks RS, Vargas-Chanes D, Jett JR. A quality-adjusted reanalysis of a Phase III trial comparing once-daily thoracic radiation vs. twice-daily thoracic radiation in patients with limited-stage small-cell lung cancer(1). Int J Radiat Oncol Biol Phys. 2002 Feb 1; 52 (2):371-81
    View PubMed
  110. Sloan JA, Bonner JA, Hillmann SL, Allmer C, Shanahan TG, Brooks BJ, Marks S, Vargas D, Jett JR. A quality-adjusted re-analysis of a phase III trial comparing once-daily thoracic radiation versus twice-daily thoracic radiation in patients with limited stage small cell lung cancer. Journal of Clinical Oncology. 2002; 52:371-81.
  111. Okuno SH, Jett JR. Small cell lung cancer: current therapy and promising new regimens. Oncologist. 2002; 7 (3):234-8
    View PubMed
  112. Nicholson SA, Okby NT, Khan MA, Welsh JA, McMenamin MG, Travis WD, Jett JR, Tazelaar HD, Trastek V, Pairolero PC, Corn PG, Herman JG, Liotta LA, Caporaso NE, Harris CC. Alterations of p14(ARF), p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma. Cancer Res. 2001 Jul 15; 61(14):5636-43.
  113. Thomas CF Jr, Tazelaar HD, Jett JR. Typical and atypical pulmonary carcinoids : outcome in patients presenting with regional lymph node involvement. Chest. 2001 Apr; 119 (4):1143-50
    View PubMed
  114. Allen MS, Jett JR, Kozelsky TF. Stage II (T3) lung cancer. Chest Surg Clin N Am. 2001 Feb; 11(1):61-7.
    View PubMed
  115. Schiller JH, Adak S, Feins RH, Keller SM, Fry WA, Livingston RB, Hammond ME, Wolf B, Sabatini L, Jett J, Kohman L, Johnson DH. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J Clin Oncol. 2001 Jan 15; 19(2):448-57.
    View PubMed
  116. Sloan J, Bonner J, Hillman S, Allmer C, Shanahan T, Brooks B, Marks R, Vargas-Chanes D, Jett J. A quality-adjusted re-analysis of a phase III trial comparing once-daily thoracic radiation in patients with limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys. 2001.
  117. Marrogi AJ, Travis WD, Welsh JA, Khan MA, Rahim H, Tazelaar H, Pairolero P, Trastek V, Jett J, Caporaso NE, Liotta LA, Harris CC. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res. 2000 Dec; 6(12):4739-44.
    View PubMed
  118. Weitz JJ, Marschke RF Jr, Sloan JA, Grill JP, Jett JR, Knost JA, Hatfield AK, Zenk DW, Bate WW, Schaefer PL. A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer. Lung Cancer. 2000 May; 28(2):157-62.
    View PubMed
  119. Adjei AA, Erlichman C, Sloan JA, Reid JM, Pitot HC, Goldberg RM, Peethambaram P, Atherton P, Hanson LJ, Alberts SR, Jett J. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol. 2000 Apr; 18 (8):1748-57
    View PubMed
  120. Midthun DE, Swensen SJ, Jett JR. Solitary pulmonary nodule: new face on an old problem. J Respir Dis. 2000; 21(4):270-276.
  121. Jett JR. Screening for lung cancer in high-risk groups: current status of low-dose spiral CT scanning and sputum markers. Seminars in Respiratory and Critical Care Medicine. 2000; 21(5):385-392.
    View PubMed
  122. Levitan N, Dowlati A, Shina D, Craffey M, Mackay W, DeVore R, Jett J, Remick S, Chang A, Johnson D. Multi-institutional phase I/II trial of paclitaxel cisplatin and etoposide with concurrent radiation for limited stage small cell lung carcinoma. Jour Clin Oncol. 2000; 18: 1102-9.
  123. Kirschling RJ, Grill JP, Marks RS, Kugler JW, Gerstner JB, Kuross SA, Michalak JC, Windschitl HE, Krewer KD, Jett JR. Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group. Am J Clin Oncol. 1999 Oct; 22(5):517-22.
    View PubMed
  124. Bonner JA, Sloan JA, Shanahan TG, Brooks BJ, Marks RS, Krook JE, Gerstner JB, Maksymiuk A, Levitt R, Mailliard JA, Tazelaar HD, Hillman S, Jett JR. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol. 1999 Sep; 17 (9):2681-91
    View PubMed
  125. Jett JR. Is there a role for adjuvant therapy for resected non-small cell lung cancer? Thorax. 1999 Aug; 54 Suppl 2:S37-41
    View PubMed
  126. Marschke RF Jr, Grill JP, Sloan JA, Wender DB, Levitt R, Mailliard JA, Gerstner JB, Ghosh C, Morton RF, Jett JR. Phase II study of high-dose somatostatin analogue in patients either previously treated or untreated who have extensive-stage small cell lung cancer. Am J Clin Oncol. 1999 Feb; 22 (1):15-7
    View PubMed
  127. Egan AJ, Boardman LA, Tazelaar HD, Swensen SJ, Jett JR, Yousem SA, Myers JL. Erdheim-Chester disease: clinical, radiologic, and histopathologic findings in five patients with interstitial lung disease. Am J Surg Pathol. 1999 Jan; 23 (1):17-26
    View PubMed
  128. Maksymiuk AW, Marschke RF Jr, Tazelaar HD, Grill J, Nair S, Marks RS, Brooks BJ, Mailliard JA, Burton GM, Jett JR. Phase II trial of topotecan for the treatment of mesothelioma. Am J Clin Oncol. 1998 Dec; 21(6):610-3.
    View PubMed
  129. Przygodzki RM, Bennett WP, Guinee DG Jr, Khan MA, Freedman A, Shields PG, Travis WD, Jett JR, Tazelaar H, Pairolero P, Trastek V, Liotta LA, Harris CC, Caporaso NE. p53 mutation spectrum in relation to GSTM1, CYP1A1 and CYP2E1 in surgically treated patients with non-small cell lung cancer. Pharmacogenetics. 1998 Dec; 8(6):503-11.
    View PubMed
  130. Bennett WP, el-Deiry WS, Rush WL, Guinee DG Jr, Freedman AN, Caporaso NE, Welsh JA, Jones RT, Borkowski A, Travis WD, Fleming MV, Trastek V, Pairolero PC, Tazelaar HD, Midthun D, Jett JR, Liotta LA, Harris CC. p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer. Clin Cancer Res. 1998 Jun; 4(6):1499-506.
    View PubMed
  131. Midthun DE, Jett JR. Early detection of lung cancer: today's approach. J Respir Dis. 1998; 19(1):59-70.
  132. Ghaemmaghami M, Jett JR. New agents in the treatment of small cell lung cancer. Chest. 1998 Jan; 113(1 Suppl):86S-91S.
    View PubMed
  133. Greenberger JS, Bahri S, Jett JR, Belani C, Kalend A, Epperly M. Considerations in optimizing radiation therapy for non-small cell lung cancer Chest. 1998; 113:46S-52S.
    View PubMed
  134. Fleming MV, Guinee DG Jr, Chu WS, Freedman AN, Caporaso NE, Bennett WP, Colby TV, Tazelaar H, Abbondanzo SL, Jett J, Pairolero P, Trastek V, Liotta LA, Harris CC, Travis WD. Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients. Hum Pathol. 1998 Jan; 29(1):60-4.
    View PubMed
  135. Arcasoy SM, Jett JR. Superior pulmonary sulcus tumors and panoasts-syndrome. N Engl J Med. 1997 Nov 6; 337(19):1370-1376.
    View PubMed
  136. Midthun DE, Jett JR. Chemotherapy for advanced lung cancer. When to expect a response. Postgrad Med. 1997 Mar; 101: (3)187-8, 191-2, 194 passim.
    View PubMed
  137. Luketich JD, Jett JR. The current management of thymic tumors. Seminars in Respiratory and Critical Care Medicine. 1997; 18(4):375-381.
  138. Strollo DC, Rosado de Christenson ML, Jett JR. Primary mediastinal tumors. Part I. Tumors of the anterior mediastinum Chest. 1997; 112:511-22.
    View PubMed
  139. Jett JR, Feins R, Kvale P, Mccloud T, Miller YW, Perry M, Sause W, Silvestri G, Stover D, Spiro S, Travis W. Pre-treatment evaluation of non-small cell lung cancer: Joint statement of the American Thoracic Society and European Respiratory Society Am J Resp Crit Care Med. 1997; 156:320-32.
    View PubMed
  140. Arcasoy SM, Bajwa MK, Jett JR. Non-hodgkin's lymphoma presenting as pancoast's syndrome Resp Med. 1997; 91:571-3.
  141. Ginsberg R, Cox J, Green M, Bulzebruck H, Grunenwald D, Harper P, Jett J, LeChevalier T, Mornex F, Scott C, Tsuchiya R. Consensus report: staging classification committee Lung Cancer. 1997; 17:S11-13.
    View PubMed
  142. Strollo DC, Rosado-di-Christenson ML, Jett JR. Primary mediastinal tumors. Part II. Tumors of the middle and posterior mediastinum Chest. 1997; 112:1334-57.
  143. Loprinzi CL, Goldberg RM, Su JQ, Mailliard JA, Kuross SA, Maksymiuk AW, Kugler JW, Jett JR, Ghosh C, Pfeifle DM, Wender DB, Burch PA. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small cell lung cancer. J Clin Oncol (Classic Papers and Current Comments). 1997; 2: (1)253-7.
  144. Harty LC, Guinee DG Jr, Travis WD, Bennett WP, Jett J, Colby TV, Tazelaar H, Trastek V, Pairolero P, Liotta LA, Harris CC, Caporaso NE. p53 mutations and occupational exposures in a surgical series of lung cancers. Cancer Epidemiol Biomarkers Prev. 1996 Dec; 5(12):997-1003.
    View PubMed
  145. Trivers GE, De Benedetti VM, Cawley HL, Caron G, Harrington AM, Bennett WP, Jett JR, Colby TV, Tazelaar H, Pairolero P, Miller RD, Harris CC. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res. 1996 Oct; 2(10):1767-75.
    View PubMed
  146. Shaw EG, Frytak S, Eagan RT, Richardson RL, Creagan ET, Jett JR, Foote RL, Su JQ, Schaid DJ, Lee RE. Etoposide-cisplatin and thoracic radiation therapy salvage of incomplete responders to a noncisplatin induction regimen for limited and extensive small-cell carcinoma of the lung. Am J Clin Oncol. 1996 Apr; 19 (2):154-8
    View PubMed
  147. Frytak S, Shaw EG, Jett JR, Richardson RL, Foote RL, Creagan ET, Eagan RT, Su JQ. Infusion cisplatin chemotherapy and hyperfractionated thoracic radiotherapy for small-cell lung cancer. Am J Clin Oncol. 1996 Apr; 19 (2):193-8
    View PubMed
  148. Castro M, Veeder MH, Mailliard JA, Tazelaar HD, Jett JR. A prospective study of pulmonary function in patients receiving mitomycin. Chest. 1996 Apr; 109 (4):939-44
    View PubMed
  149. Jett JR. Primary lung cancer. Conn's Current Therapy. 1996; 182-188.
  150. Greenberger JS, Kalend A, Sciurba F, Jett JR, Landreneau RJ, Belani CP. Development of multifield three-dimensional conformal radiotherapy of lung cancer using a total lung dose/volume histogram. Radiat Oncol Investig. 1996; 3:243-255.
    View PubMed
  151. Rowland KM Jr, Loprinzi CL, Shaw EG, Maksymiuk AW, Kuross SA, Jung SH, Kugler JW, Tschetter LK, Ghosh C, Schaefer PL, Owen D, Washburn JH Jr, Webb TA, Mailliard JA, Jett JR. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetateplacebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol. 1996 Jan; 14: (1)135-41.
    View PubMed
  152. Ghaemmaghami M, Jett JR. Small cell lung cancer: current approaches J Resp Diseases Vol 1996 Dec; 17(2):1054-68.
  153. Jett JR, Kirschling RJ, Jung SH, Marks RS. A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer: a study of the North Central Cancer Treatment Group. Semin Oncol. 1995 Jun; 22(3 Suppl 6):75-7.
    View PubMed
  154. Guinee DG Jr, Travis WD, Trivers GE, De Benedetti VM, Cawley H, Welsh JA, Bennett WP, Jett J, Colby TV, Tazelaar H, Abbondanzo SL, Pairolero P, Trastek V, Caporaso NE, Liotta LA, Harris CC. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. Carcinogenesis. 1995 May; 16(5):993-1002.
    View PubMed
  155. Midthun DE, Swensen SJ, Jett JR. Postepowanie w przypadku stwierdzenia pojedynczego cienia okraglego w plucu: Approach to the solitary pulmonary nodule Polish Journal of Medicine 1995 Jun; 2:45-53.
  156. Jett J, Kirschling R, Jung S, Marks R. A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer: A study of the North Central Cancer Treatment Group. (Presented at Taxol Investigators Workshop) Seminars in Oncology. 1995; 22:75-77.
  157. Jett JR, Su JQ, Krook JE, Goldberg RM, Kugler JW. Measurable or assessable disease in lung cancer trials: does it matter? J Clin Oncol. 1994 Dec; 12: (12)2677-81.
    View PubMed
  158. Jett JR, Maksymiuk AW, Su JQ, Mailliard JA, Krook JE, Tschetter LK, Kardinal CG, Twito DI, Levitt R, Gerstner JB. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol. 1994 Nov; 12: (11)2321-6.
    View PubMed
  159. Shaw EG, Su JQ, Eagan RT, Jett JR, Maksymiuk AW, Deigert FA. Prophylactic cranial irradiation in complete responders with small-cell lung cancer: analysis of the Mayo Clinic and North Central Cancer Treatment Group data bases. J Clin Oncol. 1994 Nov; 12 (11):2327-32
    View PubMed
  160. Loprinzi CL, Goldberg RM, Su JQ, Mailliard JA, Kuross SA, Maksymiuk AW, Kugler JW, Jett JR, Ghosh C, Pfeifle DM. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol. 1994 Jun; 12: (6)1126-9.
    View PubMed
  161. Liengswangwong V, Bonner JA, Shaw EG, Foote RL, Frytak S, Eagan RT, Jett JR, Richardson RL, Creagan ET, Su JQ. Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. J Clin Oncol. 1994 Mar; 12: (3)496-502.
    View PubMed
  162. Bunn P, Arriagada R, Choi N, Feld R, Gregor A, Jett J, Johnson B, Komaki R, Kristjansen P, Murray N, et al. Combined modality therapy in small cell lung cancer. Lung Cancer. 1994 Mar; 10 Suppl 1:S25-8.
    View PubMed
  163. Wiesenfeld M, Jett JR, Su JQ, Braich TA, Kardinal CG, Mailliard JA, Veeder MH, Morton RF, Michalak JC. Phase II trial of edatrexate in small cell lung cancer. Cancer. 1994 Feb 15; 73(4):1189-93.
    View PubMed
  164. Maksymiuk AW, Jett JR, Earle JD, Su JQ, Diegert FA, Mailliard JA, Kardinal CG, Krook JE, Veeder MH, Wiesenfeld M. Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial. J Clin Oncol. 1994 Jan; 12(1):70-6.
    View PubMed
  165. Wiesenfeld M, Jett J, Su J, Braich T, Kardinal C, Mailliard J, Veeder M, Morton R, Michalak J. Phase II trial of edatrexate in small cell lung cancer Cancer. 1994; 73:1189-1193.
  166. Pujol J, Gibney DJ, Su JQ, Maksymiuk AW, Jett JR. Immune response induced in small-celled lung cancer by maintenance therapy with interferon gamma. J Natl Cancer Inst. 1993 Nov 17; 85:1844-1850.
    View PubMed
  167. Jett JR. Current treatment of unresectable lung cancer. Mayo Clin Proc. 1993 Jun; 68 (6):603-11
    View PubMed
  168. Gesme DH, Jett JR, Schreffler DD, Su JQ, Mailliard JA, Foley JF, Krook JE, Maksymiuk AW, Hatfield AK, Ebbert LP. A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment Group. Cancer. 1993 May 1; 71(9):2723-6.
    View PubMed
  169. Midthun DE, Swensen SJ, Jett JR. Approach to the solitary pulmonary nodule. Mayo Clin Proc. 1993 Apr; 68 (4):378-85
    View PubMed
  170. Shaw EG, McGinnis WL, Jett JR, Su JQ, Frank AR, Mailliard JA, Engel RE, Wiesenfeld M, Rowland KM Jr. Pilot study of accelerated hyperfractionated thoracic radiation therapy plus concomitant etoposide and cisplatin chemotherapy in patients with unresectable stage III non-small-cell carcinoma of the lung. J Natl Cancer Inst. 1993 Feb 17; 85 (4):321-3
    View PubMed
  171. Jett JR, Tazelaar HD. Lung cancer in the elderly. Lung Biol Health Dis. 1993; 63:61-80.
  172. Gesme D, Jett J, Schreffler D, Su J, Mailliard J, Foley J, Krook J, Maksymiuk A, Hatfield A, Ebbert L, Pfeifle D, Morton R, Tschetter L, Schaefer P. A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer: A trial of the North Central Cancer Treatment Group Cancer. 1993; 71:2723-2726.
  173. Veeder MH, Jett JR, Su JQ, Mailliard JA, Foley JF, Dalton RJ, Etzell PS, Marschke RF Jr, Kardinal CG, Maksymiuk AW, Tazelaar HD. A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma. Cancer. 1992 Nov 01; 70: (9)2281-7.
    View PubMed
  174. Reinoso MA, Jett JR, Beck KC. Body plethysmography in the evaluation of intrathoracic airway abnormalities. Chest. 1992 Jun; 101 (6):1674-6
    View PubMed
  175. Midthun DE, Swensen SJ, Jett JR. Clinical strategies for solitary pulmonary nodule. Annu Rev Med. 1992; 43:195-208.
    View PubMed
  176. Morton RF, Jett JR, McGinnis WL, Earle JD, Therneau TM, Krook JE, Elliott TE, Mailliard JA, Nelimark RA, Maksymiuk AW. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med. 1991 Nov 1; 115 (9):681-6
    View PubMed
  177. Jett JR, Tazelaar HD, Keim LW, Ingrassia TS 3rd. Plastic bronchitis: an old disease revisited. Mayo Clin Proc. 1991 Mar; 66(3):305-11.
    View PubMed
  178. Holmes EC, Bleehen NM, LeChavalier T, Ettinger D, Jett JR, Johnson D, Komaki R, Saijo N, Sause W, Torovo M, VanHoutte P, Wulfrank D. Postoperative adjuvant treatments for non-small cell lung cancer: consumer report. Lung Cancer. 1991; 7:11-14.
  179. Morton R, Jett J, McGinnis W, Earle J, Therneau T, Krook J, Elliott T, Mailliard J, Nelimark R, Maksymiuk A, Drummond R, Laurie J, Kugler J, Anderson R. Randomized phase III trial of thoracic radiation therapy alone versus combined chemoradiotherapy for locally unresectable non-small cell lung cancer Ann Intern Med. 1991; 115:681-686.
  180. Goldberg RM, Jett JR, Therneau TM, Johnson PS, Tschetter LK, Krook JE, Veeder MH, Owen D, Etzell PS, Andres DF. Bolus versus infusion regimens of etoposide and cisplatin in treatment of non-small cell lung cancer: a study of the North Central Cancer Treatment group. J Natl Cancer Inst. 1990 Dec 19; 82(24):1899-903.
    View PubMed
  181. Swensen SJ, Jett JR, Payne WS, Viggiano RW, Pairolero PC, Trastek VF. An integrated approach to evaluation of the solitary pulmonary nodule. Mayo Clin Proc. 1990 Feb; 65 (2):173-86
    View PubMed
  182. Jett JR, Everson L, Therneau TM, Krook JE, Dalton RJ, Marschke RF Jr, Veeder MH, Brunk SF, Mailliard JA, Twito DI. Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group. J Clin Oncol. 1990 Jan; 8: (1)33-8.
    View PubMed
  183. Goldberg R, Jett J, Therneau T, Johnson P, Tschetter L, Krook J, Veeder M, Owen D, Etzell P, Andres D. Bolus versus infusional etoposide and cisplatinum in treatment of non-small cell lung cancer: A study of the North Central Cancer Treatment Group J Natl Cancer Inst. 1990; 82:1899-1903.
  184. Jett JR. Is there a role for interferon in the treatment of small cell lung cancer? Lung Cancer. 1989 Dec; 5(4-6):281-6.
  185. Robinow JS, Shaw EG, Eagan RT, Lee RE, Creagan ET, Frytak S, Richardson RL, Jett JR, Burton JK, Ilstrup DM. Results of combination chemotherapy and thoracic radiation therapy for unresectable non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 1989 Dec; 17 (6):1203-10
    View PubMed
  186. Sanderson DR, Jett JR. Lung cancer: the American view. Eur Respir J. 1989 Nov; 2 (10):1002-7
    View PubMed
  187. Everson LK, Jett JR, O'Fallon JR, Krook JE, Dalton RJ, Mailliard JA, Tschetter LK, Cullinan SA, Gerstner JB, Morton RF. Alternating chemotherapy with or without VP-16 in extensive-stage small-cell lung cancer. Am J Clin Oncol. 1989 Aug; 12: (4)339-44.
    View PubMed
  188. Krook JE, Jett JR, Little C. A phase I-II study of sequential infusion VP-16 and cisplatin therapy in advanced lung cancer. Am J Clin Oncol. 1989 Apr; 12(2):114-7.
    View PubMed
  189. Frytak S, Shaw JN, O'Neill BP, Lee RE, Eagan RT, Shaw EG, Richardson RL, Coles DT, Jett JR. Leukoencephalopathy in small cell lung cancer patients receiving prophylactic cranial irradiation. Am J Clin Oncol. 1989 Feb; 12 (1):27-33
    View PubMed
  190. Krook J, Jett J, Little C. A phase I-II study of sequential infusion VP16 and cisplatin therapy in advanced lung cancer Am J Clin Oncol. 1989; 12(2):114-117.
  191. Everson L, Jett J, O'Fallon J, Krook J, Dalton R, Mailliard J, Tschetter L, Cullinan S, Gerstner J, Morton R, Laurie J. Alternating chemotherapy with or without VP16 in extensive stage small cell lung cancer Am J Clin Oncol. 1989; 12(4):339-344.
  192. Mohr DN, Jett JR. Preoperative evaluation of pulmonary risk factors. J Gen Intern Med. 1988 May-Jun; 3 (3):277-87
    View PubMed
  193. Frytak S, Shaw JN, Lee RE, Eagan RT, Shaw EG, Richardson RL, Creagan ET, Coles DT, Jett JR. Treatment toxicities in long-term survivors of limited small cell lung cancer. Cancer Invest. 1988; 6 (6):669-76
    View PubMed
  194. Eagan RT, Frytak S, Richardson RL, Creagan ET, Therneau TM, Coles DT, Jett JR. A randomized comparative trial of sequential versus alternating cyclophosphamide, doxorubicin, and cisplatin and mitomycin, lomustine, and methotrexate in metastatic non-small-cell lung cancer. J Clin Oncol. 1988 Jan; 6: (1)5-8.
    View PubMed
  195. Hong WS, Jett JR, Sasaki Y, Takahashi H, Nakano H, Nakagawa K, Hoshi A, Saijo N. Colony inhibitory effect of recombinant human tumor necrosis factor (rH-TNF) and/or recombinant human interferon (rH-IFN)-alpha, -beta and -gamma on human lung cancer cell lines. Jpn J Clin Oncol. 1987 Mar; 17(1):49-55.
    View PubMed
  196. Frytak S, Eagan RT, Richardson RL, Creagan ET, Jett JR, Coles DT, Lee RE. Cyclophosphamide, etoposide, and infusion cisplatin in refractory small cell lung cancer. Am J Clin Oncol. 1987 Feb; 10:33-35.
    View PubMed
  197. Jett JR, Saijo N, Hong WS, Sasaki Y, Takahashi H, Nakano H, Nakagawa K, Sakurai M, Suemasu K, Tesada M. The colony inhibition of a new chemotherapeutic agent (KW2152) against human lung cancer cell lines. Invest New Drugs. 1987; 5 (2):155-9
    View PubMed
  198. Takahashi H, Sasaki Y, Saijo N, Sakurai M, Nakano H, Nakagawa K, Hoshi A, Jett JR, Hong WS. In vitro colony inhibition of carboplatin against stomach and lung cancer cell lines in comparison with cisplatin. Cancer Chemotherapy & Pharmacology. 1987; 19(3):197-200.
    View PubMed
  199. Ishihara J, Saijo N, Sasaki Y, Nakano H, Ozaki A, Takahashi H, Masanori S, Nakagawa K, Iigo M, Kanzawa F, Hoshi A, Hong WS, Jett JR, Takahashi T. The different effects of recombinant human tumor necrosis factor on rat fibrosarcoma sublines. Cancer Immunol Immunother. 1987; 24:185-189.
    View PubMed
  200. Adams VI, Unni KK, Muhm JR, Jett JR, Ilstrup DM, Bernatz PE. Diffuse malignant mesothelioma of pleura. Diagnosis and survival in 92 cases. Cancer. 1986 Oct 1; 58(7):1540-51.
    View PubMed
  201. Suga J, Nagahiro S, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Sakurai M, Ono R, Takahashi H, Nakano H, Nakagawa K, Hoshi A, Jett JR. Long-term survival in patients with small cell lung cancer. Jpn J Clin Oncol. 1986 Sep; 16(3):309-315.
    View PubMed
  202. Sakurai M, Iigo M, Ozaki A, Jett JR, Sasaki Y, Hoshi A, Saijo N. Inhibitory effect of murine recombinant interferon (beta) on the pulmonary metastasis of B-16 melanoma. Jpn J Cancer Res. 1986 Aug; 77(8):774-81.
    View PubMed
  203. Shinkai T, Saijo N, Eguchi K, Sasaki Y, Tominaga K, Sakurai M, Suga J, Miyaoka H, Sano T, Keicho N, Takahashi H, Ishihara J, Tamura T, Hoshi A, Jett JR. Cisplatin and vindesine combination chemotherapy for non-small cell lung cancer: a randomized trial comparing two dosages of cisplatin. Jpn J Cancer Res. 1986 Aug; 77(8):782-789.
    View PubMed
  204. Sano T, Saijo N, Sasaki Y, Shinkai T, Eguchi K, Tamura T, Sakurai M, Takahashi H, Nakano H, Tajiri H, Morinaga S, Itabashi M, Jett JR. A case report of synchronous small cell lung cancer and gastric cancer successfully treated with carboplatin. Jpn J Cancer Res. 1986 Aug; 77(8):790-798.
    View PubMed
  205. Sakurai M, Saijo N, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Sano T, Suemasu K, Jett JR. The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial. Jpn J Clin Oncol. 1986 Jun; 16(2):153-6.
    View PubMed
  206. Eagan RT, Frytak S, Creagan ET, Richardson RL, Coles DT, Jett JR. Differing response rates and survival between squamous and non-squamous non-small cell lung cancer. Comparison of CAP versus MAP. Am J Clin Oncol. 1986 Jun; 9(3):249-54.
    View PubMed
  207. Futami H, Sasaki Y, Sakurai M, Nomori H, Takahasi H, Ishihara J, Hoshi A, Koyama K, Hamburger AW, Jett JR. Differences of host immune response and of sensitivity to chemotherapeutic agents between two clones of rat fibrosarcoma with different metastatic potential. Jpn J Cancer Res. 1986 May; 77(5):480-486.
    View PubMed
  208. Mansel JK, Zinsmeister AR, Pairolero PC, Jett JR. Pulmonary resection of metastatic colorectal adenocarcinoma. A ten year experience. Chest. 1986 Jan; 89(1):109-12.
    View PubMed
  209. Krook JE, Jett JR, Fleming TR, Dalton RJ, Marschke RF, Cullinan SA, Windschitl HE, Everson LK, Brunk FS, Laurie JA. A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer. J Clin Oncol. 1985 Jun; 3: (6)842-8.
    View PubMed
  210. Adams VI, Jett JR. Diffuse malignant mesothelioma: desmoplastic variant. Tumor Diagnosis and Treatment. 1984; 11(6):1-4.
  211. Berquist TH, Brown LR, May GR, Jett JR, Bernatz PE. Magnetic resonance imaging of the chest: a diagnostic comparison with computed tomography and hilar tomography. Magn Reson Imaging. 1984; 2(4):315-27.
    View PubMed
  212. Jett JR, Kuritsky JN, Katzmann JA, Homburger HA. Acquired immunodeficiency syndrome associated with blood-product transfusions. Ann Intern Med. 1983 Nov; 99(5):621-4.
    View PubMed
  213. Jett JR, Hollinger CG, Zinsmeister AR, Pairolero PC. Pulmonary resection of metastatic renal cell carcinoma. Chest. 1983 Oct; 84(4):442-5.
    View PubMed
  214. Jett JR, Cortese DA, Fontana RS. Lung cancer: current concepts and prospects. CA Cancer J Clin. 1983 Mar-Apr; 33(2):74-86.
    View PubMed
  215. Ruiz-Arguelles A, Jett JR, Ritts RE Jr. Impaired generation of helper T cells in a patient with chronic mucocutaneous candidiases and malignant thymoma. J Clin Lab Immunol. 1983 Mar; 10:165-169.
    View PubMed
  216. Jett JR, Eagan RT. Chemotherapy for malignant mesothelioma; CAMEO. Am J Clin Oncol. 1982 Aug; 5(4):429-31.
    View PubMed
  217. Jett JR, Hoffman TM, Connor RJ, Herberman RB. Effect of various immunoregulatory substances on the growth inhibitory activity (GIA) of human monocytes against lymphoblastoid cell lines. Immunopharmacology. 1982 Apr; 4(2):105-13.
    View PubMed
  218. Ruiz-Arguelles A, Jett JR, Ritts RE Jr. Stage-associated incidence of serum circulating immune complexes in patients with untreated bronchogenic carcinoma. Cancer Immunol Immunother. 1982; 12:197-201.
  219. Jett JR, Cortese DA, Dines DE. The value of bronchoscopy in the diagnosis of mycobacterial disease. A five-year experience. Chest. 1981 Nov; 80(5):575-8.
    View PubMed
  220. Jett JR, Mantovani A, Herberman RB. Augmentation of human monocyte-mediated cytolysis by interferon. Cell Immunol. 1980 Sep 1; 54(2):425-34.
    View PubMed
  221. Roder JC, Haliotis T, Klein M, Korec S, Jett JR, Ortaldo J, Heberman RB, Katz P, Fauci AS. A new immunodeficiency disorder in humans involving NK cells. Nature. 1980 Apr 10; 284(5756):553-5.
    View PubMed
  222. Kellermann G, Jett JR, Luyten-Kellermann M, Moses HL, Fontana RS. Variation of microsomal mixed function oxidase(s) and human lung cancer. Cancer. 1980 Mar 15; 45(6):1438-42.
    View PubMed
  223. Klein M, Roder J, Haliotis T, Korec S, Jett JR, Herberman RB, et al. The Chediak-Higashi gene in humans. II. The selectivity of the defect in NK and ADCC function. J Exp Med. 1980; 151:1049-1058.
    View PubMed
  224. Herberman RB, Ortaldo JR, Djeu JY, Holden HT, Jett J, Lang NP, Rubinstein M, Pestka S. Role of interferon in regulation of cytotoxicity by natural killer cells and macrophages. Ann N Y Acad Sci. 1980; 350:63-71.
    View PubMed
  225. Jett JR, Branum EL, Fontana RS, Taylor WF, Moses HL. Macromolecular binding of 3H-benzo(a)pyrene metabolites and lymphocyte transformation in patients with lung cancer, and in smoking and nonsmoking control subjects. Am Rev Respir Dis. 1979 Aug; 120(2):369-75.
    View PubMed
  226. Jett JR, Stobo JD, Moses HL. Aryl hydrocarbon hydroxylase activity in subpopulations of peripheral blood mononuclear cells. Cancer Res. 1978; 38:1979-1982.
    View PubMed
  227. Jett JR, Moses HL, Branum EL, Taylor WF, Fontana RS. Benzo(a)pyrene metabolism and blast transformation in peripheral blood mononuclear cells from smoking and nonsmoking populations and lung cancer patients. Cancer. 1978 Jan; 41(1):192-200.
    View PubMed
  228. Kellermann G, Luyten-Kellermann M, Jett JR, Moses HL, Fontana RS. Aryl hydrocarbon hydroxylase in man and lung cancer. Hum Genet Suppl. 1978; (1):161-8.